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Abstract
Introduction Outside the intensive care unit (ICU), clinically important deep vein thrombosis (DVT) is
usually defined as a symptomatic event that leads to objective radiologic confirmation and subsequent
treatment. The objective of the present survey is to identify the patient factors and radiologic features
of lower limb DVT that intensivists consider more or less likely to make a DVT clinically important in ICU
patients.
Methods Our definition of clinically important DVT was a DVT likely to result in short-term or long-term
morbidity or mortality if left untreated, as opposed to a DVT that is unlikely to have important
consequences. We asked respondents to indicate the likelihood that patient factors and
ultrasonographic features make a DVT clinically important using a five-point scale (from 1 = much less
likely to 5 = much more likely).
Results Of the 71 Canadian intensivists who responded, 70 (99%) rated three patient factors as most
likely to make a DVT clinically important: clinical suspicion of pulmonary embolism (mean score 4.6),
acute or chronic cardiopulmonary morbidity that might limit a patient's ability to tolerate pulmonary
embolism (score 4.5), and leg symptoms (score 4.2). Of the ultrasound features, proximal (score 4.7),
large (score 4.2), and totally occlusive (score 3.9) thrombi were considered the three most important.
Conclusion When labeling a DVT as clinically important, intensivists rely on different patient specific
factors and thrombus characteristics than are used to assess the clinical importance of DVT outside
the ICU. The clinical importance of DVT is influenced by unique factors such as cardiopulmonary
reserve among mechanically ventilated patients.
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Introduction
Venous thromboembolism (VTE), which includes both deep
vein thrombosis (DVT) and pulmonary embolism (PE), is a
common complication of critical illness [1,2]. Critically ill
patients harbor many coincident risk factors for DVT, such as
the need for surgery, catheters, immobility, and use of seda-
tives and paralytic agents [3-5]. As in the noncritically ill popu-
lation, it is likely that most episodes of DVT are asymptomatic
Received: 26 January 2004
Revisions requested: 11 March 2004
Revisions received: 27 March 2004
Accepted: 05 April 2004
Published: 6 May 2004
Critical Care 2004, 8:R145-R152 (DOI 10.1186/cc2859)
This article is online at: http://ccforum.com/content/8/3/R145
© 2004 Cook et al.; licensee BioMed Central Ltd. This is an Open 
Access article: verbatim copying and redistribution of this article are 
permitted in all media for any purpose, provided this notice is preserved 
along with the article's original URL.
DVT = deep vein thrombosis; ICU = intensive care unit; PE = pulmonary embolism; SD = standard deviation; VTE = venous thromboembolism.Critical Care    June 2004  Vol 8 No 3    Cook et al.
R146
and confined to the deep veins of the calf. However, with time,
20–30% of untreated calf vein thrombi extend proximally into
the thigh, where they pose a 40–50% risk for PE [6]. Early
studies of the natural history of PE suggest that untreated PE
has a mortality rate of at least 25% [7].
One large study found PE at autopsy in 59 out of 404 hospi-
talized patients (14.6%); among the 20 patients who died from
PE, this diagnosis was not suspected in 14 (70)% [8]. In a 25-
year longitudinal study, 9% of patients had autopsy evidence
of PE; again, the diagnosis of PE was not suspected in 84%
of patients before autopsy [9]. In a landmark study highlighting
this problem in critical care practice, 13 out of 34 (38%) inten-
sive care unit (ICU) patients with known DVT who had no
symptoms of PE were diagnosed with PE by ventilation-per-
fusion scans [10]. It is possible that many mechanically venti-
lated patients with sudden episodes of hypotension,
tachycardia, or hypoxia may have undetected PE [11]. Unsus-
pected PE may also contribute to difficulty in weaning patients
from mechanical ventilation [12]. We posit that in critically ill
patients with impaired cardiopulmonary reserve, a small PE,
which might be of minimal clinical importance in patients who
are less ill, might have severe or fatal consequences [13].
Thus, the clinical consequences of DVT have the potential to
be particularly serious, but may be unrecognized in the ICU. It
is also possible that ICU patients undergoing treatment for
DVT are more likely than other patients to suffer serious com-
plications from anticoagulant therapy.
Among ambulatory patients, most clinicians consider sympto-
matic DVT to be more clinically important than asymptomatic
DVT. Some clinicians may consider clinically important DVT to
be proximal (thigh DVT) rather than distal (calf DVT), based on
the greater propensity of untreated proximal DVT to cause PE.
Thus, clinically important episodes of DVT are usually defined
as symptomatic events that lead to objective radiologic confir-
mation and subsequent treatment [2,14]. However, critically ill
patients cannot reliably communicate their symptoms, and
intensivists rarely use the reference standard of venography to
diagnose DVT [15]. Furthermore, physical signs such as uni-
lateral leg edema, which are important clinical features of DVT
outside the ICU, are uncommon in the ICU because many crit-
ically ill patients are supine and frequently have severe bilateral
edema [16]. These observations suggest that the classic def-
inition of a clinically important DVT is not suitable in the ICU
setting.
There is no objective reference standard for or definition of
clinically important DVT in critically ill patients because, to our
knowledge, no studies have systematically correlated clinical
or radiographic characteristics of acute venous thrombosis
with patient outcomes. Despite the lack of such data, the con-
cept of a clinically important DVT in the critically ill is important
because such an assessment may be used to determine
whether a DVT should be treated; in addition, a definition of
clinically important DVT could be used in future clinical
research. Therefore, as a first step toward defining a 'clinically
important DVT', we surveyed critical care physicians to identify
those patient factors and radiologic features of lower limb DVT
that influence their perceptions about the clinical importance
of DVT. Our primary hypothesis was that intensivists will con-
sider the following patient factors more likely to make a DVT
clinically important: the DVT is symptomatic, is detected by
physical examination, is found in a patient with risk factors,
occurs in a patient who has been receiving DVT prophylaxis or
therapeutic anticoagulation, and occurs in a patient with either
chronic cardiopulmonary comorbidity or acute cardiopulmo-
nary illness that might limit tolerance to a PE. Our secondary
hypothesis was that intensivists will consider the following
compression ultrasound features more likely to make a DVT
clinically important: the DVT is proximal, large, occlusive, and
persists 1 week later.
Methods
Instrument development
We developed a survey for members of the Canadian Critical
Care Trials Group who care for critically ill adults [17]. We
generated items for this instrument based on a review of the
literature, our prior work [15,18,19], and discussion among
the investigators. We reduced items for this instrument by
interviews with five intensivists who did not participate in the
survey.
Instrument formatting
In the survey we provided the rationale for the questionnaire,
defined the concept of clinically important DVT, and requested
basic demographic information about respondents and their
ICU settings. We then surveyed respondents about the extent
to which various factors influence their assessment of the clin-
ical importance of DVT in critically ill patients. A self-adminis-
tered rather than interviewer-administered format was used to
maximize the validity of self-reported information [20].
We used the following conceptual definition of clinically impor-
tant DVT: a DVT that, if untreated, would will lead to increased
short-term morbidity (e.g. cardiopulmonary consequences that
may delay weaning from mechanical ventilation), long-term
morbidity (e.g. patient-centered consequences such as
chronic venous insufficiency), or mortality. We listed potential
characteristics of clinically important DVTs in two domains:
patient factors and ultrasonographic features. For an ICU
patient with a DVT we asked respondents to indicate, using a
Likert scale, whether each of these characteristics was more
or less likely to make a DVT clinically important (1 = much less
likely to make the DVT clinically important, 2 = somewhat less
likely to make the DVT clinically important, 3 = neither more nor
less likely to make the DVT clinically important, 4 = somewhat
more likely to make the DVT clinically important, and 5 = much
more likely to make the DVT clinically important; see Appendix
1).Available online http://ccforum.com/content/8/3/R145
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Demographic questions included year of graduation from
medical school and clinical discipline (internal medicine or its
subspecialities, surgery, or anesthesia). We also requested
information about the number of ICU beds in which the
respondent works, the type of ICU (medical, surgical or mixed
medical–surgical), and the presence of a thrombosis consult
service. We used closed-ended questions for the ICU demo-
graphic data to maximize the accuracy and completeness of
responses [21].
Instrument administration
We administered the survey instrument by e-mail to all mem-
bers of the Canadian Critical Care Trial Group who care for
critically ill adults. We contacted nonrespondents by facsimile
with a second copy of the questionnaire [22], and then by e-
mail or telephone contact. The survey was conducted in Sep-
tember and October 2003.
Research ethics
Participation was voluntary, individual responses were kept
confidential, and data were anonymized upon receipt. The
study was approved by the Research Ethics Board of St
Joseph's Healthcare in Hamilton, Ontario.
Analysis
Descriptive statistics were used, including proportions with
associated confidence intervals, as well as measures of cen-
tral tendency and dispersion (mean and standard deviation
[SD]). Within each domain (patient factors and ultrasono-
graphic features), we ranked the characteristics according to
which were most likely to make the DVT clinically important.
Results
The response rate was 70 out of 71 (99%). Sixty-six (93%) of
the surveys were returned without a reminder e-mail; five (7%)
required a reminder. Clinical discipline backgrounds were
internal medicine in 52 (75%), anesthesia in eight (12%), sur-
gery in six (9%), and other in three (4%). Respondents had
16.2 (SD 8.2) years of ICU experience, and worked in ICUs
with a mean of 21.5 (SD 8.0) beds. ICUs represented were
from 31 hospitals in 16 cities in Canada; 67 (94%) of
respondents were university affiliated. Twelve out of 31 hospi-
tals (39%) had a thrombosis consultation service.
Patient factors considered to increase the clinical importance
of a DVT, ranked according to the mean score, are shown in
Table 1. A clinical suspicion of PE (mean score 4.6 [SD 0.7]),
acute or chronic cardiopulmonary morbidity that might limit a
patient's ability to tolerate PE (score 4.5 [0.7]), and the pres-
ence of leg symptoms (score 4.2 [0.8]) were most likely to
make a DVT clinically important. In Fig. 1 we present the distri-
bution of responses from 1 to 5 for patient factors associated
with clinically important DVT. The absence of risk factors,
symptoms, or physical signs of DVT, DVT associated with cen-
tral venous catheterization, and DVT in the absence of proph-
ylaxis were all considered to be less important than the other
factors in determining the clinical relevance of an ICU-
acquired DVT.
In Table 2 we present the ultrasonographic features consid-
ered likely to make a DVT clinically important, ranked accord-
ing to the mean score. Proximal location of the DVT was rated
as most likely to make a DVT clinically important (score 4.7
[SD 0.5]). Of the other ultrasound features, large (score 4.2
[0.6]) and totally occlusive (score 3.9 [0.8]) thrombi were con-
sidered most important. In Fig. 2 we present the distribution of
responses from 1 to 5 for ultrasonographic features associ-
ated with clinically important DVT. A DVT that is small, partially
occlusive, or has flow around it did not make the DVT unlikely
to be considered clinically important.
Discussion
DVT is underdiagnosed and probably undertreated in critically
ill patients. This occurs despite the high likelihood that PE is
clinically more important in the critically ill, who often have
impaired cardiopulmonary reserve [13]. We conducted the
present survey to determine which characteristics of DVT are
considered to be clinically important by intensivists. Determin-
ing which characteristics impart clinical significance is impor-
tant because the thrombi that are considered to be clinically
important are likely to be treated, and these treatments have
adverse effects such as bleeding, inconvenience, and cost
[23].
Outside the ICU setting, many clinicians consider DVT clini-
cally significant primarily when patients have referable symp-
toms and evidence of occlusive thrombosis on
ultrasonography. However, critically ill patients are generally
unable to report symptoms and uncommonly have unilateral
leg edema because they are recumbent. Therefore, 'typical'
clinical symptoms and signs cannot be used to establish the
clinical significance of a DVT in the ICU. Our survey confirmed
that intensivists use some different criteria to assign clinical
significance than are used by nonintensivists, particularly
thrombosis experts [24-26]. For example, asymptomatic DVT
detected on screening ultrasonography in critically ill patients
with severely impaired cardiorespiratory reserve are accorded
substantial clinical importance in the ICU, whereas the signifi-
cance of these thrombi may be debated by clinicians working
outside the ICU setting.
Strengths of the survey include comprehensive lists of both
patient factors and ultrasonographic features that may influ-
ence clinicians' interpretation of the importance of a DVT in the
ICU setting. Ideally, empiric data would inform us about which
DVT characteristics are most likely to be associated with
short-term and long-term morbidity and mortality in critically ill
patients. In the absence of such data, we defined clinically
important DVT as a DVT that is likely, in the opinion of the
intensivists, to result in short-term or long-term morbidity orCritical Care    June 2004  Vol 8 No 3    Cook et al.
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mortality if left untreated, as opposed to a DVT that will proba-
bly not have important consequences. We used evidence from
three randomized trials to conduct this survey; these sug-
gested that a self-administered format yields more valid self-
reports than interviewer-administered questionnaires [20],
that closed-ended formats yield more complete and valid
demographic data about the respondents than do open-ended
formats [21], and that appending second questionnaires to
reminders maximizes response rates [22]. Our respondents
represented largely university affiliated ICUs from coast to
coast in Canada, and our response rate was 99%. We believe
that our results are generalizable to similar multidisciplinary
secondary and tertiary care settings in which the majority of
mechanically ventilated, critically ill patients are cared for.
However, in focusing on the short-term consequences of VTE,
there are three major limitations of the survey. The first is that
we did not evaluate thresholds for DVT treatment in the ICU
setting, which is a more complex phenomenon. Treatment
thresholds are also influenced by other factors such as the nat-
ural history of the ICU patient's underlying illness, the type of
therapeutic options available and suitable for each patient,
intensivists' knowledge about the realistic magnitude of thera-
peutic benefits and harms, patient-specific and dynamic bal-
ance between bleeding and thrombosis risks, and alternative
options such as surveillance monitoring. Evaluating treatment
Figure 1
Patient factors considered by respondents to make a deep venous  thrombosis (DVT) clinically important in the intensive care unit setting Patient factors considered by respondents to make a deep venous 
thrombosis (DVT) clinically important in the intensive care unit setting. 
The scale used was as follows: 1 = much less likely to make the DVT 
clinically important; 2 = somewhat less likely to make the DVT clinically 
important; 3 = neither more nor less likely to make the DVT clinically 
important; 4 = somewhat more likely to make the DVT clinically impor-
tant; and 5 = much more likely to make the DVT clinically important.
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Table 1
Patient factors affecting the clinical importance of deep venous 
thrombosis in intensive care unit patients
Patient factor Mean (SD)
rating
Clinical suspicion of pulmonary embolism 4.6 (0.7)
Chronic/acute cardiopulmonary comorbidity 4.5 (0.7)
Leg symptoms 4.2 (0.8)
Occurring while receiving therapeutic anticoagulation 4.0 (1.2)
Detected by physical examination 3.8 (0.7)
Occurring while receiving thromboprophylaxis 3.6 (0.8)
At least one risk factor for venous thromboembolism 3.6 (0.6)
Associated with central venous catheterization 3.3 (0.9)
Not receiving prophylaxis 3.2 (0.7)
Not associated with central venous catheterization 3.1 (0.5)
Not receiving therapeutic anticoagulation 3.1 (0.3)
No risk factors 3.0 (0.4)
Asymptomatic 2.8 (0.5)
Not detected by physical examination 2.8 (0.5)
According to mean scores we ranked the patient factors considered 
by intensivists as likely to make a deep venous thrombosis clinically 
important. SD, standard deviationAvailable online http://ccforum.com/content/8/3/R145
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thresholds is also interesting, although it is a more complex
issue and would require different survey questions (or an alter-
native study design altogether). Second, we did not elicit
views on the risks, costs, and consequences of investigating
and managing treatment complications such as bleeding.
Third, we did not consider the long-term consequences of
DVT such as postphlebitic syndrome, which may be associ-
ated with disabling symptoms and/or ulceration among
survivors.
Experts express varying views on the appropriate end-points
for studies of thromboprophylaxis [27-31]. Over the years, the
majority of thromboprophylaxis trials have used DVT detected
by sensitive screening methods such as venography as the pri-
mary efficacy outcome. Only one of two randomized trials in
the ICU has employed ultrasonographic followed by veno-
graphic screening for DVT [32], and venograms are rarely per-
formed in critical care practice today [15]. The clinical
importance of DVT identified by screening tests outside the
ICU is controversial. Two lines of evidence support the
hypothesis that DVT detected by screening tests is clinically
unimportant. The first line of evidence is the fact that even with
use of appropriate VTE prophylaxis, 15–30% of patients
undergoing major orthopedic surgery will be discharged from
the hospital with venographically detectable calf or more prox-
imal DVT; fewer (about 3% of such patients) ultimately return
with a symptomatic DVT [33].
The second line of evidence is that, even when clinicians per-
form screening ultrasonography at the time of hospital dis-
charge and then treat patients who have DVT with
Figure 2
Ultrasonographic factors considered by respondents to make a deep  venous thrombosis (DVT) clinically important in the intensive care unit  setting Ultrasonographic factors considered by respondents to make a deep 
venous thrombosis (DVT) clinically important in the intensive care unit 
setting. The scale used was as follows: 1 = much less likely to make the 
DVT clinically important; 2 = somewhat less likely to make the DVT clin-
ically important; 3 = neither more nor less likely to make the DVT clini-
cally important; 4 = somewhat more likely to make the DVT clinically 
important; and 5 = much more likely to make the DVT clinically 
important.
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Table 2
Ultrasonographic features affecting the clinical importance of 
deep venous thrombosis in intensive care unit patients
Ultrasonographic feature Mean (SD) Rating
Proximal DVT 4.7 (0.5)
Large DVT 4.2 (0.6)
Totally occlusive DVT 3.9 (0.8)
No flow on color Doppler ultrasound 3.6 (0.7)
DVT still present 1 week after diagnosis 3.6 (0.7)
Partially occlusive DVT 3.3 (0.7)
Flow on color Doppler ultrasound 3.0 (0.6)
DVT not extending into deep system 2.7 (1.0)
Localized DVT 2.7 (0.7)
Small DVT 2.6 (0.6)
DVT not present 1 week after diagnosis 2.3 (0.8)
Distal DVT 2.0 (0.7)
According to mean scores we ranked the ultrasonographic features 
considered by intensivists as likely to make a deep venous 
thrombosis (DVT) clinically important. SD, standard deviationCritical Care    June 2004  Vol 8 No 3    Cook et al.
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antithrombotic therapy, there is no evidence that the subse-
quent risk for thrombosis is decreased. For example, Robinson
and colleagues [34] randomized patients after orthopedic sur-
gery to undergo screening ultrasonography or sham ultra-
sonography. After hospital discharge the risk for patients
returning with clinical symptoms of venous thrombosis was the
same, irrespective of whether patients underwent ultrasonog-
raphy, suggesting that thrombi identified by screening ultra-
sonography in hospitalized patients are not necessarily
destined to produce clinical symptoms. As a result of these
observations, routine screening of such patients for DVT at the
time of hospital discharge has effectively been abandoned [2].
Caution is needed, however, in extrapolating this practice pat-
tern to critically ill patients. For example, patients in the ICU fre-
quently have significantly impaired cardiorespiratory reserve.
Therefore, they may be unable to tolerate a small PE that an
otherwise healthy outpatient might tolerate easily. Better qual-
ity evidence on the clinical impact of DVT diagnosed by
screening ultrasound in the critically ill is needed. Meanwhile,
most such patients with lower limb DVT diagnosed by screen-
ing ultrasonography appear to be treated, based on recent
studies [5]. Interpreting studies about VTE in the ICU requires
consideration of the clinical importance of the DVT end-points.
In future randomized trials testing the efficacy of thrombo-
prophylaxis interventions, we recommend that validated and
feasible screening tests, such as Doppler ultrasonography or
serial Doppler ultrasonography, be used [31]. Large, simple
randomized trials that use clinically important VTE end-points
should follow, consisting of events such as symptomatic or
fatal PE, and ultrasonographically diagnosed proximal DVT
[28-31].
The results of this survey can inform our research program on
VTE in the ICU. We conclude that most forms of VTE are con-
sidered to be clinically serious, perhaps more so than in
patients outside the critical care setting, supporting the need
for ongoing research in this area. From this survey we gener-
ated new information showing how the critical care context is
important to intensivists caring for patients with DVT. Develop-
ment of DVT in the critically ill patient may have unique conse-
quences, particularly in patients requiring mechanical
ventilation, vasopressors, or inotropes, because intensivists
report that cardiopulmonary reserve is crucial in interpreting
the features of a DVT that make it clinically important. Our
results also suggest that treatment thresholds used by inten-
sivists may be lower than the treatment thresholds employed
by other clinicians, although this hypothesis can be formally
tested. On the other hand, the treatment threshold may be
higher for intensivists who take into account other complica-
tions of critical illness. For example, dynamic bleeding and
thrombotic risks in ICU patients must be traded off when con-
sidering whether to treat a DVT, and with what to treat it. Such
factors will influence the associated morbidity and mortality of
VTE in the ICU setting, which need to be more rigorously
evaluated.
Conclusion
We demonstrated that intensivists define clinically important
DVT using criteria that are relevant to critical care patients in
addition to those suitable for general DVT patients. Pending
the availability of data that correlate clinical outcomes with the
criteria we studied in this survey, these concepts could be
used in future studies of the prevention and treatment of DVT
in the critically ill.
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Key messages
1. Determining which DVT characteristics impart clinical 
significance to intensivists is important because DVT 
considered to be clinically important are likely to be 
treated, and treatments have adverse effects such as 
bleeding, inconvenience and cost.
2. In this survey of intensivists, we defined a clinically 
important DVT as one that, if untreated, would will lead 
to increased short term morbidity, long term morbidity, 
or mortality.
3. The 3 patient factors reported as most likely to make a 
DVT clinically important were clinical suspicion of PE, 
acute or chronic cardiopulmonary morbidity which 
might limit the tolerability of a PE, and leg symptoms.
4. The 3 ultrasound features reported as most likely to 
make a DVT clinically important were proximal location, 
large size, and total vessel occlusion.
5. The clinical importance of DVT according to intensivists 
is influenced by unique ICU factors such as cardiopul-
monary reserve among mechanically ventilated 
patients.          Available online http://ccforum.com/content/8/3/R145
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